Thermo Fisher cuts 300 jobs in viral vector manufacturing amid 2025 biopharma layoffs, driven by economic pressures, R&D shifts, and pipeline failures.
Vertex's non-opioid pain drug is approved by FDA, offering effective relief by targeting sodium channels, eliminating addiction risks and opioid side effects.
New study highlights affordable alternatives to GLP-1 drugs for effective weight loss, including metformin, berberine, and sustainable lifestyle changes.
AstraZeneca allocates $570M for Canadian expansion, creating 700+ jobs and boosting R&D, solidifying Canada as a global life sciences innovation hub.
Discover how mergers and acquisitions in biotech and pharma are reshaping 2025, driven by innovation, patent cliffs, and regulatory shifts under new policies.
What Trump's CMS can and can't change in 2025: Medicare drug price negotiations aim to lower costs, but challenges with innovation and industry pushback remain.
Indonesia targets 200m free medical checkups improving human capital to support Prabowo's 8% growth goal by boosting workforce productivity and reducing health costs.
Pharma share analysis 2025: Discover trends such as mRNA technology, biotechnology and AI. Opportunities, risks and forecasts for investors at a glance.
Pfizer's Phase 3 trial of gene therapy for Duchenne muscular dystrophy shows no significant results. Future research will be supported by detailed data.
FDA approval of HYMPAVZI™: Advancement in hemophilia treatment with weekly prophylaxis and reduced bleeding risk. Learn more about the safety.